drugset

drugset / Trial / NCT03612154

Study of Lorlatinib in ROS1 Rearranged NSCLC

NCT03612154 ↗

Phase 2 Unknown 35 enrolled National Cancer Center, Korea

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.

Timeline

Start: 2019-05-02
Primary completion: 2022-12-31
Completion: 2023-12-31

Publications

Ahn BC, Kim YJ, Lee Y, Suh KJ, Kim SH, Kim DW, Kim TM, Lee KH, Han JY. Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2026 Jan 1;12(1):84-89. doi: 10.1001/jamaoncol.2025.5097.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lorlatinib	Small molecule	100 mg	Oral

Indications